Abstracts tagged "ANA and Diagnostic Tests"

Abstract Number: 701 • 2017 ACR/ARHP Annual Meeting
Variability in ICAP (International Consensus on ANA Patterns) Pattern Reporting in Testing for Antinuclear Antibodies (ANA) By Indirect Immunofluorescence Assay (IFA)
Stanley J. Naides¹, Jonathan Genzen², Gyorgy Abel³, Christine Bashleben⁴ and Mohammad Qasim Ansari⁵, ¹Immunology, Quest Diagnostics Nichols Institute, San Juan Capistrano, CA, ²ARUP Laboratories Inc, Salt Lake City, UT, ³Department of Pathology and Laboratory Medicine, Lahey Clinic Burlington, Burlington, VT, ⁴College of American Pathologists, Northfield, IL, ⁵Department of Pathology and Laboratory Medicine, Louis Stokes VAMC, Cleveland, OH
Background/Purpose: ANA IFA pattern may guide clinical evaluation by directing specific antibody testing. ICAP has defined consensus ANA IFA patterns and the level of competency…
Abstract Number: 2846 • 2016 ACR/ARHP Annual Meeting
Application of a Novel Anti-Nuclear Antibody Multiplex Test Using Finger Stick and Venous Whole Blood in a Rheumatology Clinic – Demonstration of Feasibility
Smitha Reddy¹, Dana Copland Reddy², Rufus Burlingame³, Vicki Nelson⁴, Carol Buchner⁴, John Stewart⁵, Sasi Mudumba⁵, John Custodio⁵, Jue Wang⁵, Randy Romero⁵, Alice Wu⁶, Carli Cherwein⁵, Simon Smith⁵ and Martin A. Gleeson⁴, ¹Arthritis Care and Research Center, San Diego, CA, ²SD Rheumatology, Chula Vista, CA, ³Genaltye, San Diego, CA, ⁴Genalyte, Wateridge circle, CA, ⁵Genalyte, San Diego, CA, ⁶Genalyte, Inc., San Diego, CA
Background/Purpose: Multiplex assays that measure anti-nuclear autoantibodies (ANA) in real time using whole blood were developed on the Maverick(TM) instrument (Genalyte, Inc., USA). Because the…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].